A5048611754- Immunotherapy and Immune Responses
- Cervical Cancer and HPV Research
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- vaccines and immunoinformatics approaches
- Virus-based gene therapy research
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- Hepatitis B Virus Studies
- RNA Interference and Gene Delivery
- Monoclonal and Polyclonal Antibodies Research
- Immune Response and Inflammation
- Endometrial and Cervical Cancer Treatments
- Cancer Research and Treatments
- Herpesvirus Infections and Treatments
- T-cell and Retrovirus Studies
- Glycosylation and Glycoproteins Research
- Colorectal and Anal Carcinomas
- Viral-associated cancers and disorders
- S100 Proteins and Annexins
- Xenotransplantation and immune response
- HIV Research and Treatment
- interferon and immune responses
- Vaccine Coverage and Hesitancy
- Prostate Cancer Treatment and Research
University of Southern California
2016-2025
Southern California University for Professional Studies
2004-2024
USC Norris Comprehensive Cancer Center
2007-2023
Keck Hospital of USC
2014-2015
University of Hawaiʻi at Mānoa
2009-2014
University of Hawaii System
2009-2014
Cancer Research Center
2009-2014
Cancer Center of Hawaii
2009-2012
Institute for Women's Policy Research
2011
Texas Tech University Health Sciences Center
2011
The relationship between binding affinity for HLA class I molecules and immunogenicity of discrete peptide epitopes has been analyzed in two different experimental approaches. In the first approach, potential ranging MHC over a 10,000-fold range was HLA-A*0201 transgenic mice. second antigenicity approximately 100 hepatitis B virus (HBV)-derived epitopes, all carrying A*0201 motifs, assessed by using PBL acute patients. both cases, it found that an threshold 500 nM (preferably 50 or less)...
Abstract Cytotoxic T lymphocyte (CTL) peptide epitopes can be used for immunization of mice against lethal virus infection. To study whether this approach successful virus‐induced tumors we generated a B6 (H‐2 b ) tumorigenic cell line transformed by human papillomavirus (HPV). This is detected in over 90% all cervical cancers. identify vaccine candidates, set 240 overlapping peptides derived from the HPV type 16 (HPV16) oncogenes E6 and E7. These were tested their ability to bind H‐2K H‐2D...
Abstract The mechanism of tumor-associated T cell dysfunction remains an unresolved problem tumor immunology. Development defects in tumor-bearing hosts are often associated with increased production immature myeloid cells. In mice, these cells represented by a population Gr-1+ this study we investigated effect on function. were isolated from MethA sarcoma or C3 mice using sorting. These expressed marker CD11b and MHC class I molecules, but they lacked expression II molecules. Tumor-induced...
Abstract The impact of the MHC class I peptide binding stability on immunogenicity particular Ags in I-restricted cytotoxic T lymphocyte responses is not clearly established. Therefore, we have determined dissociation rate each from at 37 degrees C and compared this to that a consensus CTL epitope. Newly defined immunogenic peptides formed relatively stable MHC-peptide complexes as shown by their low rates, whereas nonimmunogenic displayed high rates. In addition virtually all previously...
Abstract Human papillomavirus type 16 (HPV16) is strongly associated with cervical carcinogenesis. The HPV16 E6 and E7 oncoproteins are constitutively expressed in the majority of tumor cells are, therefore, attractive targets for CTL-mediated immunotherapy. In mice, outgrowth a lethal dose HPV16-induced has been prevented by vaccination CTL epitope encoded E7, indicating feasibility peptide immunization to obtain antitumor responses. present study, immunogenicity 9 HLA-A*0201-binding...
Manipulations capable of breaking host tolerance to induce tissue-specific T cell-mediated inflammation are central importance tumor immunotherapy and our understanding autoimmunity. We demonstrate that androgen ablative therapy induces profuse cell infiltration benign glands tumors in human prostates. is readily apparent after 7–28 days comprised predominantly a response by CD4+ cells comparatively fewer CD8+ cells. Also, within the treated prostate exhibit restricted TCR Vβ gene usage,...
We have measured the binding affinity for five HLA-A alleles: HLA-A1 (A*0101), A2.1 (A*0201), A3 (A*0301), A11 (A*1101), and A24 (A*2401); of a set all possible nonamer peptides (n = 240) human papillomavirus type 16 E6 E7 proteins. High were identified each alleles, thus allowing us to select several candidates CTL-based vaccines. Moreover, this unbiased allowed an evaluation predictive value HLA motifs derived either from analysis sequencing pools naturally processed or polyalanine...
The only peptide of Sendai virus that is recognized by cytotoxic T lymphocytes (CTL) in B6 mice was found with (i) the use recombinant vaccinia constructs containing separate genes and (ii) a set overlapping peptides completely spanning identified nucleoprotein (NP) gene product. This immunodominant NP virus-specific CTL are known to have therapeutic effects vivo. By subcutaneous immunization, this induced peptide-specific memory responses Most importantly, had been immunized were protected...
Papillomavirus-like particles (VLPs) are a promising prophylactic vaccine candidate to prevent human papillomavirus (HPV) infections and associated epithelial neoplasia. However, they unlikely have therapeutic effects because the virion capsid proteins not detected in proliferating cells of infected epithelia or cervical carcinomas. To increase number viral antigen targets for cell-mediated immune responses VLP-based vaccine, we generated stable chimeric VLPs consisting L1 major protein plus...
Vaccination with synthetic peptides representing cytotoxic T lymphocyte (CTL) epitopes can lead to a protective CTL-mediated immunity against tumors or viruses. We now report that vaccination CTL epitope derived from the human adenovirus type 5 E1A-region (Ad5E1A234-243), which serve as target for tumor-eradicating CTL, enhances rather than inhibits growth of Ad5E1A-expressing tumors. This adverse effect peptide was rapidly evoked, required low doses (10 micrograms), and achieved by mode...
Abstract The central role of the p53 tumor suppressor gene product in oncogenesis is gradually being clarified. Point mutations are common most human cancers and often associated with protein overexpression. Overexpressed wild‐type or mutant determinants thus represent an attractive target for immunotherapy cancer directed against a structure involved malignant transformation. An important step towards this goal identification epitopes that can be recognized by cytotoxic T lymphocytes. We...
Negative co-stimulatory signaling mediated via cell surface programmed death (PD)-1 expression modulates T and B activation is involved in maintaining peripheral tolerance. In this study, we examined the effects of a fully human PD-1-abrogating antibody on vitro expansion function vaccine-induced CD8+ cells (CTLs) specific for melanoma-associated antigens glycoprotein 100 (gp100) melanoma antigen recognized by (MART)-1. PD-1 blockade during peptide stimulation augmented absolute numbers...
Blood transfusion before organ transplantation has a beneficial effect on allograft survival; the mechanism of this remained mystery. In murine models, presence common histocompatibility antigens in blood donor and recipient favors induction tolerance.
The tumor suppressor protein p53 is overexpressed in close to 50% of all human malignancies. therefore an attractive target for immunotherapy. Cytotoxic T lymphocytes (CTLs) recognizing a murine wild-type peptide, presented by the major histocompatibility complex class I molecule H-2Kb, were generated immunizing gene deficient (p53 −/−) C57BL/6 mice with syngeneic p53-overexpressing cells. Adoptive transfer these CTLs into tumor-bearing +/+ nude caused complete and permanent eradication....